Patents Expiring in April 2035
✉ Email this page to a colleague
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-001 | May 23, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-002 | May 23, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-003 | May 23, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-004 | May 23, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE | ||||
Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |